Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.fjc.0000175455.46245.c8PMID 16116345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia

  2005cited by this paper
• Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors

  2004cited by this paper
• The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.

  2004cited by this paper
• Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.

  2004cited by this paper
• Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.

  2004cited by this paper
• Simvastatin inhibits interleukin‐6 release in human monocytes stimulated by C‐reactive protein and lipopolysaccharide

  2003cited by this paper
• Inhibition of Rho Family GTPases Results in Increased TNF-α Production After Lipopolysaccharide Exposure 1

  2003cited by this paper
• Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease.

  2003cited by this paper
• Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells

  2003cited by this paper
• Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.

  2003cited by this paper
• Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.

  2003cited by this paper
• Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients

  2003cited by this paper
• Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation

  2003cited by this paper
• Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia

  2003cited by this paper
• Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.

  2003cited by this paper
• Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome.

  2002cited by this paper
• Cytokines in the Pathogenesis of Atherosclerosis

  2002cited by this paper
• Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients

  2002cited by this paper
• Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.

  2002cited by this paper
• Anti-inflammatory effect of cerivastatin in vascular injury independent of serum cholesterol and blood pressure lowering effects in mouse model.

  2002cited by this paper
• Zytokine in der Pathogenese der Atherosklerose

  2002cited by this paper
• Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.

  2002cited by this paper
• The many faces of tumor necrosis factor in stroke

  2002cited by this paper
• C-reactive protein, inflammation, and innate immunity

  2001cited by this paper
• Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.

  2001cited by this paper
• Interleukin-1 and related proteins in cardiovascular disease in adults and children.

  2001cited by this paper
• Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 Cells

  2000cited by this paper
• Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

  2000cited by this paper
• Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells.

  2000cited by this paper
• Pravastatin down-regulates inflammatory mediators in human monocytes in vitro.

  2000cited by this paper
• Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.

  2000cited by this paper
• Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.

  2000cited by this paper
• Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia.

  2000cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.

  1998cited by this paper
• Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

  1998cited by this paper
• Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

  1996cited by this paper
• Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages.

  1995cited by this paper

• Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies.

  2022cites this paper
• Nature versus Number: Monocytes in Cardiovascular Disease

  2021influential citation
• Aliskiren and Fenofibrate Constrict Liver Fibrosis by means of Focusing on TGF-β1/Smad Signaling Pathway and Actuating HGF Expression

  2021cites this paper
• Breakfast skipping and prevalence of heartburn syndrome among Iranian adults

  2020cites this paper
• Obesity: Role of Tumor Necrosis Factor-α and of Other Adipocytokines Involved in the Chronic Inflammation and the Immune and Metabolic Dysregulation

  2019cites this paper
• Cell signaling and biological pathway in cardiovascular diseases

  2019cites this paper
• Fluvastatin for lowering lipids.

  2018cites this paper
• Lipid-lowering efficacy of rosuvastatin.

  2017cites this paper
• Association of Statins With Decreased Acute Pancreatitis Severity: A Propensity Score Analysis

  2017cites this paper
• Metformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro

  2016cites this paper
• Metformin reduces the expression of NADPH oxidase and increases the expression of antioxidative enzymes in human monocytes/macrophages cultured in vitro.

  2016cites this paper
• Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner

  2016cites this paper
• Effects of Prednisolone, L-Asparaginase, Gemfibrozil, and Combinations of These Elements on Mice Lipid Profile, Liver, and Pancreas

  2016cites this paper
• Cellular and molecular influences on pro-thrombotic and pro-inflammatory states in young patients with coronary artery disease

  2016cites this paper
• Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages

  2015cites this paper
• Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus

  2015cites this paper
• Anti-inflammatory effects of bromocriptine in a patient with autoimmune polyglandular syndrome type 2.

  2014cites this paper
• Molecular Determinants of Atherosclerosis

  2014cites this paper
• Транскрипционная регуляция в патогенезе хронических заболеваний желудочно-кишечного тракта: роль рецепторов, активирующих пролиферацию пероксисом

  2014cites this paper
• Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.

  2014cites this paper
• Interleukin-7 and Interleukin-15 for Cancer

  2014cites this paper
• Effects of corticosteroid treatment on high-density lipoprotein distribution and function

  2014cites this paper
• Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance

  2013cites this paper
• The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.

  2013cites this paper
• Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.

  2013cites this paper
• The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma

  2012cites this paper
• Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells

  2012cites this paper
• Omega-3 fatty acids enhance monocyte-suppressing effect of bezafibrate in patients with isolated hypertriglyceridemia.

  2012cites this paper
• Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure

  2012cites this paper
• Fenofibrate Reduces C-Reactive Protein Levels in Hypertriglyceridemic Patients With High Risks for Cardiovascular Diseases

  2012cites this paper
• Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia.

  2011cites this paper
• A Systems Biology Strategy for Predicting Similarities and Differences of Drug Effects: Evidence for Drug-specific Modulation of Inflammation in Atherosclerosis

  2011cites this paper
• Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose.

  2011cites this paper
• Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.

  2011cites this paper
• Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials

  2011influential citation
• Coexistence of primary aldosteronism and Hashimoto’s thyroiditis

  2011cites this paper
• Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.

  2011cites this paper
• Effect of Bezafibrate on Monocyte Cytokine Release and Systemic Inflammation in Patients With Impaired Fasting Glucose

  2011cites this paper
• The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia

  2011cites this paper
• Signaling in Atherosclerosis

  2011cites this paper
• The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis.

  2011cites this paper
• Effects of the new adiponectin paralogous protein CTRP-3 and of LPS on cytokine release from monocytes of patients with type 2 diabetes mellitus.

  2010cites this paper
• Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance.

  2010cites this paper
• Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?

  2010cites this paper
• Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

  2010cites this paper
• Estatinas y factor de necrosis tumoral alfa

  2010cites this paper
• Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes

  2010cites this paper
• Role of TNF-α in vascular dysfunction

  2009cites this paper
• Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study

  2009cites this paper
• Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes.

  2009cites this paper
• Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia

  2009cites this paper
• Pleiotropic effects of fenofibrate.

  2009cites this paper
• TNF‐α, a potent lipid metabolism regulator

  2009influential citation
• High-density lipoproteins, inflammation and oxidative stress.

  2009cites this paper
• Anti-inflammatory effects of fibrates: an overview.

  2009cites this paper
• Chronic Disease, sleep quality, and TNF-alpha: Understanding Pathophysiologic Processes

  2009cites this paper
• Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

  2008cites this paper
• Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-α Agonist for Treating Cardiovascular Disease

  2007cites this paper
• Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists

  2007cites this paper
• IL‐7 Modulates Osteoclastogenesis in Patients Affected by Solid Tumors

  2007cites this paper
• El monocito/macrófago como diana terapéutica en la aterosclerosis

  2007cites this paper
• Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.

  2007cites this paper
• Statins and the Risk of Pneumonia: A Population‐Based, Nested Case‐Control Study

  2007cites this paper
• Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease

  2006cites this paper
• P eroxisome Proliferator-Activated Receptors at the rossroads of Obesity , Diabetes , and Cardiovascular Disease

  2006cites this paper
• IL-7 Up-Regulates TNF-α-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor

  2006cites this paper
• Alcohol Use, Vascular Disease, and Lipid-Lowering Drugs

  2006cites this paper
• Neuropeptides induced a pronounced and statin-sensitive dysregulation of mevalonate cycle in human monocytes of patients with hypercholesterolemia.

  2006cites this paper
• Korean Circulation Journal

  year unknowncites this paper